Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis.
COVID-19
QTc
QTc prolongation
SARS-CoV-2
chloroquine
coronavirus
hydroxychloroquine
torsades de pointes
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
13 May 2021
13 May 2021
Historique:
received:
20
03
2021
revised:
25
04
2021
accepted:
08
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Hydroxychloroquine or chloroquine with or without the concomitant use of azithromycin have been widely used to treat patients with SARS-CoV-2 infection, based on early in vitro studies, despite their potential to prolong the QTc interval of patients. This is a systematic review and metanalysis designed to assess the effect of hydroxychloroquine with or without the addition of azithromycin on the QTc of hospitalized patients with COVID-19. PubMed, Scopus, Cochrane and MedRxiv databases were reviewed. A random effect model meta-analysis was used, and I-square was used to assess the heterogeneity. The prespecified endpoints were ΔQTc, QTc prolongation > 500 ms and ΔQTc > 60 ms. A total of 18 studies and 7179 patients met the inclusion criteria and were included in this systematic review and meta-analysis. The use of hydroxychloroquine with or without the addition of azithromycin was associated with increased QTc when used as part of the management of patients with SARS-CoV-2 infection. The combination therapy with hydroxychloroquine plus azithromycin was also associated with statistically significant increases in QTc. Moreover, the use of hydroxychloroquine alone, azithromycin alone, or the combination of the two was associated with increased numbers of patients that developed QTc prolongation > 500 ms. This systematic review and metanalysis revealed that the use of hydroxychloroquine alone or in conjunction with azithromycin was linked to an increase in the QTc interval of hospitalized patients with SARS-CoV-2 infection that received these agents.
Sections du résumé
BACKGROUND
BACKGROUND
Hydroxychloroquine or chloroquine with or without the concomitant use of azithromycin have been widely used to treat patients with SARS-CoV-2 infection, based on early in vitro studies, despite their potential to prolong the QTc interval of patients.
OBJECTIVE
OBJECTIVE
This is a systematic review and metanalysis designed to assess the effect of hydroxychloroquine with or without the addition of azithromycin on the QTc of hospitalized patients with COVID-19.
MATERIALS AND METHODS
METHODS
PubMed, Scopus, Cochrane and MedRxiv databases were reviewed. A random effect model meta-analysis was used, and I-square was used to assess the heterogeneity. The prespecified endpoints were ΔQTc, QTc prolongation > 500 ms and ΔQTc > 60 ms.
RESULTS
RESULTS
A total of 18 studies and 7179 patients met the inclusion criteria and were included in this systematic review and meta-analysis. The use of hydroxychloroquine with or without the addition of azithromycin was associated with increased QTc when used as part of the management of patients with SARS-CoV-2 infection. The combination therapy with hydroxychloroquine plus azithromycin was also associated with statistically significant increases in QTc. Moreover, the use of hydroxychloroquine alone, azithromycin alone, or the combination of the two was associated with increased numbers of patients that developed QTc prolongation > 500 ms.
CONCLUSION
CONCLUSIONS
This systematic review and metanalysis revealed that the use of hydroxychloroquine alone or in conjunction with azithromycin was linked to an increase in the QTc interval of hospitalized patients with SARS-CoV-2 infection that received these agents.
Identifiants
pubmed: 34068104
pii: jcdd8050055
doi: 10.3390/jcdd8050055
pmc: PMC8152730
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069
pubmed: 32936266
Circulation. 2008 Apr 29;117(17):2184-91
pubmed: 18427136
Heart Vessels. 2021 Jan;36(1):115-120
pubmed: 32676695
JAMA Cardiol. 2020 Sep 1;5(9):986-987
pubmed: 32936259
Int J Cardiol. 2020 Oct 1;316:280-284
pubmed: 32439366
Int J Antimicrob Agents. 2020 Mar;55(3):105923
pubmed: 32070753
J Cardiovasc Electrophysiol. 2020 Aug;31(8):1904-1907
pubmed: 32485061
Br J Clin Pharmacol. 2021 Mar;87(3):1150-1154
pubmed: 32687645
J Autoimmun. 2020 Jul;111:102468
pubmed: 32317220
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041
pubmed: 32936252
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Heart Rhythm. 2020 Sep;17(9):1425-1433
pubmed: 32407884
Circulation. 2020 Jun 16;141(24):e906-e907
pubmed: 32267732
Neth Heart J. 2020 Jul;28(7-8):418-423
pubmed: 32648153
Epidemiol Infect. 2020 Jun 22;148:e124
pubmed: 32605683
Clin Pharmacokinet. 2020 Jun;59(6):659-669
pubmed: 32306288
J Electrocardiol. 2006 Oct;39(4 Suppl):S123-7
pubmed: 16920145
Int J Antimicrob Agents. 2020 May;55(5):105938
pubmed: 32171740
Heart Rhythm. 2020 Sep;17(9):1472-1479
pubmed: 32438018
J Am Heart Assoc. 2020 Jun 16;9(12):e017144
pubmed: 32463348
Lancet Infect Dis. 2007 Aug;7(8):549-58
pubmed: 17646028
Circulation. 2020 Jul 7;142(1):7-9
pubmed: 32286863
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
BMC Med. 2018 Nov 7;16(1):200
pubmed: 30400791
Cardiovasc Toxicol. 2017 Oct;17(4):434-440
pubmed: 28213753
J Antimicrob Chemother. 2017 May 1;72(5):1272-1274
pubmed: 28160473
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662
pubmed: 32347743
J Interv Card Electrophysiol. 2007 Apr;18(3):243-6
pubmed: 17546486
Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1364-8
pubmed: 18216262
N Engl J Med. 2004 Mar 4;350(10):1013-22
pubmed: 14999113
J Clin Rheumatol. 2013 Aug;19(5):286-8
pubmed: 23872551
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Cardiol Young. 2020 Oct;30(10):1482-1485
pubmed: 32686633
Neth Heart J. 2020 Jul;28(7-8):406-409
pubmed: 32350818
Heart Rhythm. 2015 Oct;12(10):2186-94
pubmed: 26025323
J Pharmacol Exp Ther. 2002 Oct;303(1):218-25
pubmed: 12235254
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Heart Rhythm. 2020 Nov;17(11):1960-1966
pubmed: 32621881
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120